Linked Life Data

20044128

Source:http://linkedlifedata.com/resource/pubmed/id/20044128

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-2-15
pubmed:abstractText
Randomized phase 3 trials have demonstrated the utility of a regimen of carboplatin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer, and have provided provocative data suggesting a substantially lower risk of carboplatin-associated hypersensitivity if PDL is delivered in combination with the platinum agent.
pubmed:grant
http://linkedlifedata.com/resource/pubmed/grant/CA04919, http://linkedlifedata.com/resource/pubmed/grant/CA13612, http://linkedlifedata.com/resource/pubmed/grant/CA25224, http://linkedlifedata.com/resource/pubmed/grant/CA27057, http://linkedlifedata.com/resource/pubmed/grant/CA32102, http://linkedlifedata.com/resource/pubmed/grant/CA35119, http://linkedlifedata.com/resource/pubmed/grant/CA35178, http://linkedlifedata.com/resource/pubmed/grant/CA35431, http://linkedlifedata.com/resource/pubmed/grant/CA3576, http://linkedlifedata.com/resource/pubmed/grant/CA38926, http://linkedlifedata.com/resource/pubmed/grant/CA45560, http://linkedlifedata.com/resource/pubmed/grant/CA45807, http://linkedlifedata.com/resource/pubmed/grant/CA46441, http://linkedlifedata.com/resource/pubmed/grant/CA58658, http://linkedlifedata.com/resource/pubmed/grant/CA63844, http://linkedlifedata.com/resource/pubmed/grant/CA67575, http://linkedlifedata.com/resource/pubmed/grant/CA76132, http://linkedlifedata.com/resource/pubmed/grant/U10 CA032102-30
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1095-6859
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
323-5
pubmed:dateRevised
2011-7-25
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
pubmed:affiliation
University of Texas, M.D. Anderson Cancer Center, Unit 1435, Houston, TX 77030, USA. mmarkman@mdanderson.org
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III, Research Support, N.I.H., Extramural